Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone nasal spray for bulimia nervosa
2016-003107-65Phase 2Completed
- Sponsor
- Opiant Pharmaceuticals
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naloxone in bulimia nervosa (BN), sponsored by Opiant Pharmaceuticals. Started Nov 2016; status: completed.
02
Drugs
naloxone
03
Conditions
bulimia nervosa (BN)
Beyond the preview
Go deeper on 2016-003107-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003107-65.